Emine ÖKSÜZOĞLU, Çiydem TIRINOĞLU, Barış KERİMOĞLU

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

Background/aim: DNA topoisomerases are ubiquitous enzymes that regulate conformational changes in DNA topology during essential cellular processes, and, for this reason, have been characterized as the cellular targets of a number of anticancer drugs. Bortezomib is a powerful proteasome inhibitor used in the treatment of hematological malignancies. In this study, we investigated the inhibitory effects of bortezomib on human topoisomerase I and II enzymes both alone and in combination modes with camptothecin and etoposide. Materials and methods: The interactions of these drugs with topoisomerase enzymes were evaluated by relaxation assay in cell-free systems. IC50 values of the drugs on topoisomerase enzymes were calculated using the S probit analysis program. Results: Bortezomib showed a very weak inhibition effect on topoisomerase I (IC50 = 87.11 mM). On the other hand, it had a strong inhibitory effect on topoisomerase II (IC50 = 1.41 mM). Our results indicated that bortezomib is effective not only on proteasome but also on topoisomerase II. In addition, bortezomib possesses an increased synergistic effect when used in combination with camptothecin and etoposide than when used alone. Conclusion: The results of this study point out that these data may build a framework for combination studies with bortezomib, camptothecin, and etoposide in the treatment of cancer.

PDF

___

1. Blade J, Ciberia TM, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 2005; 44: 440-448.
2. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5-18.
3. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-513.
4. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13: 5291-5294.
5. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11: 239-253.
6. Maxwell T, Bates A. Topo 2008: DNA topoisomerases in biology and medicine. Nucleic Acids Res 2009; 37: 3.
7. Wang JC. DNA Topoisomerases. Ann Rev Biochem 1996; 65: 635-692.
8. Ting CY, Hsu CT, Hsu HT, Su JS, Chen TY, Tarn WY, Kuo YH, Jacqueline WP, Liu LF, Hwang J. Isodiospyrin as a novel human DNA topoisomerase I inhibitor. Biochem Pharm 2003; 66: 1981-1991.
9. Nitiss JL. Investigating the biological function of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 998; 1400: 63-81.
10. Champoux JJ. DNA topoisomerases: structure, function and mechanism. Annu Rev Biochem 2001; 70: 369-413.
11. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013; 8: 82-95.
12. Seaton A, Higgins C, Mann J, Baron A, Bailly C, Neidle S, Van Den Berg H. Mechanistic and anti-proliferate studies of two novel, biologically active bis-Benzimidazoles. Eur J Cancer 2003; 39: 2548-2555.
13. Hsiang YH, Hertzberg R, Hecht S, Liu LF. CPT induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-14878.
14. Svejstrup JQ, Christiansen K, Gromova II, Andersen AH, Westergaard O. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I: the mode of action of CPT at a specific recognition site. J Mol Biol 1991; 222: 669-678.
15. Baldwin, EL, Osheroff, N. Etoposide, topoisomerase II and cancer. Curr Med Chem-Anti-Cancer Agents 2005; 5: 363-372.
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
17. Halligan BD, Edwards KA, Liu LF. Purification and characterization of type II DNA topoisomerase from bovine calf thymus. J Biol Chem 1985; 260: 2475-2482.
18. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L seeds extract and its b-carboline alkaloids. J Pharm Pharmaceut Sci 2002; 5: 19-23.
19. Cho KH, Pezzuto JM, Bolton JL, Steele VE, Kelloff GJ, Lee SK, Constantinou A. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur J Cancer 2000; 36: 2146-2156.
20. Barrett JF, Sutcliffe JA, Gootz TD. In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother 1990; 34: 1-7.
21. Pinar A, Yurdakul P, Yildiz I, Temiz-Arpaci O, Acan NL, Aki-Sener E, Yalcin I Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors. Biochem Biophys Res Commun 2004; 317: 670-674.
22. Kaplan-Ozen C, Tekiner-Gulbas B, Foto E, Yildiz I, Diril N, Aki E, Yalcin I. Benzothiazole derivatives as human DNA topoisomerase IIα inhibitors. Med Chem Res 2013; DOI 10.1007/s00044-013-0577-5.
23. Zilifdar F, Alper-Hayta S, Yilmaz S, Kaplan-Ozen C, Foto E, Aydogan Z, Yildiz I, Aki E, Yalcin I, Diril N. Genotoxic potentials and eukaryotic DNA topoisomerase I inhibitory effects of some benzoxazine derivatives. Med Chem Res 2014; 23: 480-486.
24. Cavo M. Current Status of Bortezomib in the Treatment of Multiple Myeloma. Curr Hematol Malig R 2007; 2: 128-137.
25. Lu DY. Drug combinations. In: Personalized Cancer Chemotherapy. An Effective Way of Enhancing Outcomes in Clinics. Woodhead Publishing: Sawston, Cambridge, UK; 2015; pp. 37-41.
26. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007; 7: 216-223.
27. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001; 37: 69-82.
28. Camacho KM, Kumar S, Menegatti S, Vogus DR, Anselmo AC, Mitragotri S. Synergistic antitumor activity of camptothecin doxorubicin combinations and their conjugates with hyaluronic acid. J Control Release 2015; 210: 198-207.
29. Petrioli P, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience. Clinical Lung Cancer 2015; 16: 229-234.
30. Kaufman JK, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer 2010; 116: 3143-3151.